Research Papers:

Targeting Notch-1 positive acute leukemia cells by novel fucose-bound liposomes carrying daunorubicin

Michihiro Ono, Rishu Takimoto, Takahiro Osuga, Yutaka Okagawa, Masahiro Hirakawa, Makoto Yoshida, Yohei Arihara, Naoki Uemura, Naoki Hayasaka, Shogo Miura, Teppei Matsuno, Fumito Tamura, Yasushi Sato, Tsutomu Sato, Satoshi Iyama, Koji Miyanishi, Kohichi Takada, Masayoshi Kobune and Junji Kato _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:38586-38597. https://doi.org/10.18632/oncotarget.9558

Metrics: PDF 1273 views  |   HTML 1520 views  |   ?  


Michihiro Ono1,*, Rishu Takimoto1,2,*, Takahiro Osuga1, Yutaka Okagawa1,2, Masahiro Hirakawa1, Makoto Yoshida1, Yohei Arihara1,2, Naoki Uemura1,2, Naoki Hayasaka1,2, Shogo Miura1,2, Teppei Matsuno1,2, Fumito Tamura1 Yasushi Sato1, Tsutomu Sato1,3, Satoshi Iyama1, Koji Miyanishi1, Kohichi Takada1, Masayoshi Kobune3, Junji Kato1,2

1Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan

2Division of Clinical Oncology, Sapporo Medical University Graduate School of Medicine, Sapporo, Japan

3Division of Molecular Oncology, Sapporo Medical University Graduate School of Medicine, Sapporo, Japan

*These authors have contributed equally to this work

Correspondence to:

Junji Kato, email: [email protected]

Keywords: AML, Notch-1, targeting, liposome, L-fucose

Received: August 25, 2015     Accepted: May 06, 2016     Published: May 23, 2016


Complete remission by induction therapy in acute myelogenous leukemia (AML) can be achieved due to improvements in supportive and optimized therapy. However, more than 20% of patients will still need to undergo salvage therapy, and most will have a poor prognosis. Determining the specificity of drugs to leukemia cells is important since this will maximize the dose of chemotherapeutic agents that can be administered to AML patients. In turn, this would be expected to lead to reduced drug toxicity and its increased efficacy. We targeted Notch-1 positive AML cells utilizing fucose-bound liposomes, since activation of Notch-1 is required for O-fucosylation. Herein, we report that intravenously injected, L-fucose-bound liposomes containing daunorubicin can be successfully delivered to AML cells that express fucosylated antigens. This resulted in efficient tumor growth inhibition in tumor-bearing mice and decreased proliferation of AML patient-derived leukemia cells. Thus, biological targeting by fucose-bound liposomes that takes advantage of the intrinsic characteristics of AML cells could be a promising new strategy for Notch-1 positive-AML treatment.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9558